Radioligand Therapy Market Growth and Demand Forecast Report, 2030

Posted by Aryan on March 5th, 2025

According to the latest market research study published by P&S Intelligence, the radioligand therapy market has experienced significant growth, with its size estimated at ,205.9 million in 2024. Projections indicate a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030, reaching approximately ,350.6 million by 2030. This expansion is primarily driven by the increasing number of FDA-approved drugs exhibiting low side effects, coupled with heightened research activities in cancer treatment. Additionally, the rising demand for more effective therapeutic options has further propelled market growth.

Government initiatives, such as the European Commission's "Europe’s Beating Cancer Plan" launched in February 2021, aim to enhance cancer services with a focus on prevention and early diagnosis. In 2022, the European government allocated over .2 billion to cancer research and care, underscoring the commitment to combating the disease. These efforts have bolstered the adoption of radiopharmaceuticals and radiotherapy, known for their efficacy in treating malignancies, thereby augmenting market growth.

Key Insights

Segmentation Analysis:

• Indication: The market is segmented based on indications, with prostate cancer and neuroendocrine tumors being the primary focus areas.
• Drug: Key drugs in the market include Lutathera, Pluvicto, Xtandi, Xofigo, and Zytiga.
• End User: Major end users encompass hospitals, clinics, and academic and research institutes.
• Distribution Channel: The distribution channels are categorized into direct and indirect channels.

Regional and Geographical Trends:

• Largest Region: North America holds the largest share of the radioligand therapy market, attributed to advanced healthcare infrastructure and significant research investments.​
• Fastest-Growing Region: The Asia-Pacific region is anticipated to exhibit the fastest growth, driven by increasing healthcare expenditure and rising awareness about advanced cancer therapies.​

Technological Advancements Shaping the Market:

• Advancements in radiopharmaceuticals have led to the development of targeted therapies with minimal side effects, enhancing patient outcomes.​
• The establishment of centralized radio-pharmacies has streamlined the availability and distribution of radioligand therapies, improving accessibility for healthcare providers and patients.​

Competitive Dynamics, Major Players, and Emerging Opportunities:

• The market is characterized as fragmented, with numerous players contributing to its dynamics.
• Key players are focusing on the development, approval, and launch of advanced radioligand therapies to meet the growing demand.
• Emerging opportunities include the exploration of radioligand therapies for a broader range of cancer types and the integration of novel technologies to enhance treatment efficacy.

The radioligand therapy market is poised for substantial growth, driven by technological advancements, strategic government initiatives, and the continuous efforts of industry players to innovate and expand therapeutic options.

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

Contact:
Chandra Mohan
AVP – Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Follow Us: LinkedIn Twitter